1. An inhalable nanoparticle enabling virulence factor elimination and antibiotics delivery for pneumococcal pneumonia therapy.
- Author
-
Dong H, Zhao Y, Li S, Wang Q, Li M, Zhao K, Zhang Z, Shi J, Zhao X, and Liu J
- Subjects
- Animals, Administration, Inhalation, Humans, Catalase administration & dosage, Catalase metabolism, Lung microbiology, Lung metabolism, Hydrogen Peroxide, Female, Mice, Mice, Inbred BALB C, Drug Delivery Systems, A549 Cells, Pneumonia, Pneumococcal drug therapy, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents therapeutic use, Virulence Factors, Streptococcus pneumoniae drug effects, Nanoparticles administration & dosage, Nanoparticles chemistry
- Abstract
Streptococcus pneumoniae (S. pneumoniae) is a major cause of community-acquired pneumonia. Current standard clinical therapies mainly focus on combating S. pneumoniae through antibiotics. However, the limited delivery of antibiotics and the undetoxified hydrogen peroxide (H
2 O2 ) virulence factor secreted by S. pneumoniae impede the therapeutic outcomes. Here we report an inhalable catalase (CAT)-tannic acid (TA) nanoassembly for local antibiotic (levofloxacin) delivery and simultaneously neutralizing the secreted H2 O2 virulence factors to treat pneumococcal pneumonia. After aerosol inhalation, the inhalable formulation (denoted as CT@LVX) effectively accumulates in lung tissues through TA-mediated mucoadhesion. CAT can reduce alveolar epithelial cells apoptosis by catalyzing the decomposition of accumulated H2 O2 in the infected lung tissues. In synergy with antibiotic LVX-mediated S. pneumoniae elimination, CT@LVX significantly decreases lung injury companied with reduced inflammatory, resulting in 100 % survival of mice with pneumonia. In a clinically isolated S. pneumoniae strain-induced pneumonia mouse model, CT@LVX also shows superior outcomes compared to the traditional antibiotic treatment, highlighting its potential clinical application prospects., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF